EZH2在葡萄膜黑色素瘤患者中的表达及其与预后的关系。
Expression of EZH2 in uveal melanomas patients and associations with prognosis.
作者信息
Cheng Ying, Li Ying, Huang Xin, Wei Wenbin, Qu Yi
机构信息
Department of Geriatrics, Qilu Hospital of Shandong University, Jinan, China.
Beijing Tongren Hospital, Capital Medical University, Beijing Tongren Eye Center, Beijing Ophthalmology and Visual Science Key Laboratory, Beijing, China.
出版信息
Oncotarget. 2017 Jul 22;8(44):76423-76431. doi: 10.18632/oncotarget.19462. eCollection 2017 Sep 29.
PURPOSE
To analyze the prognostic value and potential target for therapeutic intervention of enhancer of zeste homologue 2 (EZH2) in uveal melanomas (UM) patients.
METHOD
We analyzed EZH2 expression in 89 primary UM patients by immuno- histochemistry to observe the clinicopathological and prognostic value of EZH2.
RESULTS
The high levels of mitoses count and Ki67 labeling index had significant correlation with overexpression EZH2 (R = 0.408, P.
CONCLUSION
Our critical finding is that overexpression EZH2 in UM can be served as predictive marker and is associated with adverse clinical outcomes. Further observation of EZH2 as a potential therapeutic target in UM is necessary.
目的
分析zeste同源物2增强子（EZH2）在葡萄膜黑色素瘤（UM）患者中的预后价值及治疗干预的潜在靶点。
方法
我们通过免疫组织化学分析了89例原发性UM患者的EZH2表达，以观察EZH2的临床病理及预后价值。
结果
高有丝分裂计数和Ki67标记指数与EZH2过表达显著相关（R = 0.408，P.
结论
我们的关键发现是UM中EZH2过表达可作为预测标志物，并与不良临床结局相关。有必要进一步观察EZH2作为UM潜在治疗靶点的情况。
Zotero 插件